Human VEGF QuantiGlo ELISA Kit
掲載日情報:2016/08/18 現在Webページ番号:111384
R&D Systems製のHuman VEGFを測定するELISAキットです。
※本製品は研究用です。研究用以外には使用できません。
[在庫・価格 :2025年04月26日 00時00分現在]
詳細 | 商品名 |
|
文献数 | ||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
VEGF, Human, ELISA Kit, QuantiGlo, 2nd Generation (96 well) |
|
24 | |||||||||||||||||||||||||||||||||||||||||||||||||||
|
[在庫・価格 :2025年04月26日 00時00分現在]
VEGF, Human, ELISA Kit, QuantiGlo, 2nd Generation (96 well)
文献数: 24
- 商品コード:QVE00B
- メーカー:RSD
- 包装:1kit
- 価格:¥135,000
- 在庫:無(未発注)
- 納期:10日程度 ※※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。
- 法規制等:カルタヘナ該当品
説明文 | 測定範囲:6.4-20,000 pg/mL,感度:5.99 pg/mL,測定試料:Serum, Plasma, Cell Culture Supernatant, Urine, Saliva,種交差性:Human,検出方法:化学発光,アッセイ法:サンドイッチELISA,アッセイ数:96 well,別売品コントロール:#QC198,測定時間:5.5 hours,測定因子:VEGF Chemiluminescent 別名:MVCD1 Genbank No: 7422 |
||
---|---|---|---|
法規制等 | カルタヘナ該当品 | ||
保存条件 | 4℃ | 法規備考 | |
掲載カタログ |
|
||
製品記事 | QuantiGlo Chemiluminescent Sandwich ELISA Kit |
||
関連記事 |
追加しました。
Product Details
- Assay Type
- Solid Phase Sandwich ELISA
- Format
- 96-well strip plate
- Assay Length
- 5.5 hours
- Sample Type & Volume Required Per Well
- Cell Culture Supernates (50 µL), Serum (50 µL), EDTA Plasma (50 µL), Heparin Plasma (50 µL), Saliva (50 µL), Urine (50 µL)
- Sensitivity
- 5.99 pg/mL
- Assay Range
- 6.4 - 20,000 pg/mL (Serum, Heparin Plasma, Saliva, Cell Culture Supernates, EDTA Plasma, Urine)
- Specificity
- Natural and recombinant human VEGF. This assay also recognizes recombinant human VEGF165b.
- Interference
- Interference observed with 1 or more available related molecules.
追加しました。
Product Summary
The QuantiGlo Human VEGF Chemiluminescent Immunoassay is a 5.5 hour solid phase ELISA designed to measure VEGF165 levels in cell culture supernates, serum, plasma, saliva, and urine. It contains Sf 21-expressed recombinant human VEGF165 and antibodies raised against the recombinant protein. Results obtained for naturally occurring human VEGF and recombinant human VEGF121 showed linear curves that were parallel to the standard curves obtained using the QuantiGlo kit standards. These results indicate that this kit can be used to determine relative mass values for natural human VEGF.
追加しました。
Precision
Intra-Assay Precision (Precision within an assay)
Four samples of known concentration were tested on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays)
Four samples of known concentration were tested in separate assays to assess inter-assay precision.
Cell Culture Supernates, Serum, EDTA Plasma, Heparin Plasma, Saliva
Intra-Assay Precision | Inter-Assay Precision | |||||||
Sample | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 |
n | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 |
Mean | 22.2 | 392 | 1,857 | 13,972 | 22.7 | 389 | 1,843 | 13,411 |
Standard Deviation | 1.76 | 12.9 | 52.3 | 557 | 2 | 27.6 | 131 | 562 |
CV% | 7.9 | 3.3 | 2.8 | 4 | 8.8 | 7.1 | 7.1 | 4.2 |
Intra-Assay Precision | Inter-Assay Precision | |||||||
Sample | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 |
n | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 |
Mean | 24.4 | 417 | 1,999 | 14,245 | 22.9 | 383 | 1,823 | 12,825 |
Standard Deviation | 1.24 | 16 | 44.9 | 608 | 2.36 | 28.9 | 141 | 536 |
CV% | 5.1 | 3.8 | 2.2 | 4.3 | 10.3 | 7.5 | 7.7 | 4.2 |
追加しました。
Recovery
The recovery of VEGF spiked to three different levels throughout the range of the assay in various matrices was evaluated.
Sample Type | Average % Recovery | Range % |
Cell Culture Media (n=4) | 103 | 95-113 |
Serum (n=4) | 102 | 90-112 |
EDTA Plasma (n=4) | 104 | 98-110 |
Heparin Plasma (n=4) | 104 | 96-111 |
Urine (n=4) | 99 | 90-106 |
追加しました。
Linearity
To assess the linearity of the assay, samples containing or spiked with high concentrations of VEGF in various matrices were diluted with Calibrator Diluent to produce samples with values within the dynamic range of the assay.
追加しました。
Additional Infomation
- Molecule Information
- VEGF
- Aliases
- VAS; Vasculotropin; VEGFA; VPF
- Entrez Gene IDs
- 7422 (Human); 22339 (Mouse); 83785 (Rat); 403802 (Canine); 493845 (Feline); 30682 (Zebrafish)
- Background
- VEGF
- Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. The amino acid sequence of VEGF exhibits primary structural, as well as limited amino acid sequence, homology with that of the A and B chains of PDGF. All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Based on its homology with VEGF, PlGF was also proposed to be an angiogenic factor. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF with high affinity.In vitro, VEGF is a potent endothelial cell mitogen. In cultured endothelial cells, VEGF can activate phospholipase C and induce rapid increases of free cytosolic Ca2+. VEGF has been shown to stimulate von Willebrand factor release from endothelial cells and induce expression of tissue factor activity in endothelial cells as well as in monocytes. VEGF has also been shown to be chemotactic for monocytes and osteoblasts. In vivo, VEGF can induce angiogenesis as well as increase microvascular permeability. As a vascular permeability factor, VEGF acts directly on the endothelium and does not degranulate mast cells. It promotes extravasation of plasma fibrinogen, leading to fibrin deposition which alters the tumor extracellular matrix. The modified extracellular matrix subsequently promotes the migration of macrophages, fibroblasts and endothelial cells. Based on its in vitro and in vivo properties, VEGF is expected to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors. Elevated levels of VEGF have been reported in synovial fluids of rheumatoid arthritis patients and in sera from cancer patients.
追加しました。
Citations
Citations of cell biology reagents in peer reviewed literature can be used as a direct measure of product quality. They can also provide crucial insightinto their use under specialized or unique experimental conditions. Because of the importance published citations have to researchers, R&D Systems personnelmanually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but alsoprovides information about sample types, species, and experimental conditions.
Vascular endothelial growth factor-A (VEGF-A) and chemokine ligand-2 (CCL2) in Amyotrophic Lateral Sclerosis (ALS) patients.
Gupta PK, Prabhakar S
J Neuroinflammation 2011 8:47
Species: Human
Sample Type: CSF
Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.
Alberts DS, Baker AF, Brewer MA, Chambers SK, Clouser MC, Cohen JL, Cui H, Gordon AN, Gordon MS, Hatch KD, Isaacs JD, Janicek MF, Nagle RB, Roe DJ, Wright HM
Clin. Cancer Res. 2010 16:5320-8
Species: Human
Sample Type: Urine
Regulation of angiogenic factors by HDM2 in renal cell carcinoma.
Ashcroft M, Carroll VA
Cancer Res. 2008 68:545-52
Species: Human
Sample Type: Cell Culture Supernates
Clinical correlations and prognostic relevance of HGF, VEGF AND FGF expression in Brazilian patients with non-Hodgkin lymphoma.
Alves A, Baiocchi O, Colleoni G, Dalboni M, Etto L, Lacerda E, Silva M, Silva V, Vettore A
Leuk. Lymphoma 2008 49:257-64
Species: Human
Sample Type: Serum
Gene transfer of matrix metalloproteinase-9 induces tumor regression of breast cancer in vivo.
Bendrik C, Dabrosin C, Gauldie J, Robertson J
Cancer Res. 2008 68:3405-12
Species: Human
Sample Type: Tissue Homogenates
Dietary lariciresinol attenuates mammary tumor growth and reduces blood vessel density in human MCF-7 breast cancer xenografts and carcinogen-induced mammary tumors in rats.
Airio M, Dings RP, M??kel?? S, Saarinen NM, Smeds AI, Warri A
Int. J. Cancer 2008 123:1196-204
Species: Human
Sample Type: Cell Culture Supernates
Selective inhibition of MEK1/2 reveals a differential requirement for ERK1/2 signalling in the regulation of HIF-1 in response to hypoxia and IGF-1.
Ahmed A, Ashcroft M, Chau NM, Cook S, Hayat S, Le Floch R, Perusinghe N, Pouyssegur J, Sutton KM, Yang J
Oncogene 2007 26:3920-9
Species: Human
Sample Type: Cell Culture Supernates
Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer.
Kut C, Mac Gabhann F, Popel AS
Br. J. Cancer 2007 97:978-85
Species: Human
Sample Type: Serum
Very low density lipoprotein receptor, a negative regulator of the wnt signaling pathway and choroidal neovascularization.
Chen Y, Flannery JG, Hu Y, Lu K, Ma JX
J. Biol. Chem. 2007 282:34420-8
Species: Human
Sample Type: Cell Culture Supernates
Sphingosine kinase 1 is up-regulated during hypoxia in U87MG glioma cells. Role of hypoxia-inducible factors 1 and 2.
Anelli V, Cheng AB, Gault CR, Obeid LM
J. Biol. Chem. 2007 283:3365-75
Species: Human
Sample Type: Cell Culture Supernates
追加しました。
製品情報は掲載時点のものですが、価格表内の価格については随時最新のものに更新されます。お問い合わせいただくタイミングにより製品情報・価格などは変更されている場合があります。
表示価格に、消費税等は含まれていません。一部価格が予告なく変更される場合がありますので、あらかじめご了承下さい。